This phase Ib study aims to evaluate applicability of touchscreen-based cognitive test battery for assessment of ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers. Additionally, the study aims to assess whether ketamine-induced cognitive deficits are reversed by modafinil using touchscreen-based test battery for testing of cognition.
Ketamine-induced schizophrenia-like cognitive deficits in healthy volunteers are measured by using touchscreen-based cognitive tests. In addition, the study aims to assess whether ketamine-induced cognitive deficits detected by touchscreen-based cognitive tests are reversed by modafinil.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
16
Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
Modafinil tablet 100 mg placed in a capsule
University of Eastern Finland, Clinical Research Centre, Brain Research Unit
Kuopio, Finland
Ketamine-induced cognitive deficits
Ketamine-induced cognitive deficits are measured by using the touchscreen cognitive test battery
Time frame: 15-60 min after initiation of ketamine or placebo infusion
Effect of modafinil on ketamine-induced cognitive deficits
The effect of modafinil on ketamine-induced cognitive deficits are measured by using the touchscreen cognitive test battery
Time frame: 15-60 min after initiation of ketamine or placebo infusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0.9 % NaCl infusion solution
Placebo capsule for modafinil capsule